Biologic Treatments for Moderate to Severe Atopic Dermatitis

FDA grants priority review for dupilumab in pediatric AD
January 31, 2020

The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.

Tralokinumab meets endpoints for all phase 3 studies
December 16, 2019

LEO Pharma has recently announced that all three phase 3 studies examining the safety and efficacy of the atopic dermatitis investigational drug tralokinumab met all of its primary and secondary endpoints, leading way to the company now seeking marketing authorization for the drug.

Fast Track designation granted to lebrikizumab for atopic dermatitis
December 11, 2019

The U.S. FDA has granted Dermira with a Fast Track designation for its atopic dermatitis drug lebrikizumab following the start of phase 3 clinical trials to examine the efficacy, tolerability and safety of the drug.